KPMG 2025 Global Life Sciences CEO Outlook

Our research finds that Life Sciences CEOs are confident in industry growth fueled by innovation, technological advancement, and operational efficiency. There is a strong appetite for mergers and acquisitions, substantial investments in AI and digitalization, and a critical need to empower the workforce to navigate rapid change. While sustainability and ESG remain high on the agenda for Life Sciences organizations globally, there are shifting priorities across regions.

2025 Life Sciences CEO Outlook

Explore how leaders in the sector are navigating industry challenges and shaping their strategies for long-term success.

Download the report

Key findings

Organizations that have already adapted their growth strategies due to interrelated challenges

Life sciences: 80%
Cross sector average: 72%

86%

have a moderate-to-high appetite for M&A over the next three years

25%

integrate the costs and ROI of sustainability initiatives into every major capital investment

73%

expect most corporate staff to be working in hybrid models within three years

Hear from our leaders

Despite market uncertainty, industry confidence is rising, with 83% of Life Sciences CEOs optimistic about growth as they balance innovation with operational efficiency. CEOs are moving beyond pilots and operationalizing AI while investing in workforce readiness and upskilling. Sustainability and ESG remain high on the agenda, shifting from compliance to strategy, with approaches tailored by region.

Koen Van Ende

Partner, Head of Life Sciences

KPMG in Belgium